Acute mountain sickness: Pathophysiology, prevention, and treatment

Progress in Cardiovascular Diseases

Volumn 52, Issue 6, 2010, Pages 467-484

  Imray, Chris ^a,b,c   Wright, Alex ^b,d   Subudhi, Andrew ^e,f   Roach, Robert ^e  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b Birmingham Medical Research Society   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

High; Hypoxia; Pathophysiology; Review

Indexed keywords

ACETAZOLAMIDE; ALMITRINE; CALCIUM CHANNEL BLOCKING AGENT; CARBOHYDRATE; DEXAMETHASONE; FUROSEMIDE; GABAPENTIN; GINKGO BILOBA EXTRACT; HYDROCORTISONE; IBUPROFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MAGNESIUM; MEDROXYPROGESTERONE; MEPHENYTOIN; METHAZOLAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PARACETAMOL; PHENAZONE; PLACEBO; PREDNISOLONE; SILDENAFIL; SPIRONOLACTONE; SUMATRIPTAN; TADALAFIL; TEMAZEPAM; THEOPHYLLINE; UNINDEXED DRUG; VASCULOTROPIN; VERAPAMIL;

ACIDOSIS; ACUTE DISEASE; ALTITUDE ACCLIMATIZATION; ALTITUDE DISEASE; ARTERIAL OXYGEN TENSION; ARTICLE; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN SIZE; CARBOHYDRATE DIET; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DIURESIS; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG WITHDRAWAL; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPOXIA; INTRACRANIAL PRESSURE; LOW DRUG DOSE; LUNG EDEMA; METABOLIC ACIDOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; SIDE EFFECT; TASTE DISORDER;

ACCLIMATIZATION; ACUTE DISEASE; ALTITUDE; ALTITUDE SICKNESS; BRAIN EDEMA; CARBONIC ANHYDRASE INHIBITORS; HUMANS; MOUNTAINEERING; OXYGEN INHALATION THERAPY; PULMONARY EDEMA; TREATMENT OUTCOME;

EID: 77952193705     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.02.003     Document Type: Article

References (185)

1. Hackett P.H., Roach R.C. High altitude cerebral edema. High Alt Med Biol 2004, 5:136-146.
2. Whymper E., Shipton E. Travels amongst the great andes of the equator 1972, Charles Knight, London, England.
3. Ravenhill T.H. Some experiences of mountain sickness in the Andes. J Trop Med Hygiene 1913, 1620:313-320.
4. Silber E., Sonnenberg P., Collier D.J., et al. Clinical features of headache at altitude: a prospective study. Neurology 2003, 60:1167-1171.
5. Serrano-Duenas M. High altitude headache. A prospective study of its clinical characteristics. Cephalalgia 2005, 25:1110-1116.
6. Hackett P.H., Rennie D. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 1976, 2:1149-1155.
7. Roach R.C., Bärtsch P., Oelz O., et al. The Lake Louise acute mountain sickness scoring system. Hypoxia and molecular medicine 1993, 272-274. Queen City Press, Burlington, VT. J.R. Sutton, C.S. Houston, G. Coates (Eds.).
8. Sampson J.B., Cymerman A., Burse R.L., et al. Procedures for the measurement of acute mountain sickness. Aviat Space Environ Med 1983, 54:1063-1073.
9. Wagner D.R., Tatsugawa K., Parker D., et al. Reliability and utility of a visual analog scale for the assessment of acute mountain sickness. High Alt Med Biol 2007, 8:27-31.
10. West J.B. Barometric pressures on Mt. Everest: new data and physiological significance. J Appl Physiol 1999, 86:1062-1854.
11. Hackett P.H., Roach R.C. High altitude medicine. Wilderness Medicine: Management of Wilderness and Environmental Emergencies 1995, 1-37. Mosby, St. Louis. 3rd ed. P.S. Auerbach (Ed.).
12. Webb J.D., Coleman M.L., Pugh C.W. Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci 2009.
13. Matsuzawa Y., Kobayashi T., Shinozaki S., et al. Low hypoxic ventilatory response and relative hypoventilation in acute mountain sickness. Jpn J Mountain Med 1990, 10.
14. Moore L.G., Harrison G.L., McCullough R.E., et al. Low acute hypoxic ventilatory response and hypoxic depression in acute altitude sickness. J Appl Physiol 1986, 60:1407-1412.
15. Leaf D.E., Goldfarb D.S. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. J Appl Physiol 2007, 102:1313-1322.
16. Hansen J., Sander M. Sympathetic neural overactivity in healthy humans after prolonged exposure to hypobaric hypoxia. J Physiol 2003, 546:921-929.
17. Kamimori G.H., Ryan E.J., Otterstetter R., et al. Catecholamine levels in hypoxia-induced acute mountain sickness. Aviat Space Environ Med 2009, 80:376-380.
18. Severinghaus J.W., Chiodi H., Eger E.I., et al. Cerebral blood flow in man at high altitude. Role of cerebrospinal fluid pH in normalization of flow in chronic hypoxia. Circ Res 1966, 19:274-282.
19. Buck A., Schirlo C., Jasinksy V., et al. Changes of cerebral blood flow during short-term exposure to normobaric hypoxia. J Cereb Blood Flow Metab 1998, 18:906-910.
20. Subudhi A.W., Panerai R.B., Roach R.C. Acute hypoxia impairs dynamic cerebral autoregulation: results from two independent techniques. J Appl Physiol 2009, 107:1165-1171.
21. Subudhi A., Panerai R., Roach R. Effects of hypobaric hypoxia on cerebral autoregulation. Stroke 2010.
22. Jansen G.F., Krins A., Basnyat B., et al. Cerebral autoregulation in subjects adapted and not adapted to high altitude. Stroke 2000, 31:2314-2318.
23. Hannon J.P., Chinn K.S., Shields J.L. Effects of acute high altitude exposure on body fluids. Fed Proc 1969, 28:1178-1184.
24. Hannon J.P., Shields J.L., Harris C.W. Effects of altitude acclimatization on blood composition of women. J Appl Physiol 1969, 26:540-547.
25. Smith T.G., Balanos G.M., Croft Q.P., et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 2008, 586:5999-6005.
26. Smith T.G., Talbot N.P., Privat C., et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA 2009, 302:1444-1450.
27. Schneider M., Bernasch D., Weymann J., et al. Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exerc 2002, 34:1886-1891.
28. Scherrer U., Rexhaj E., Jayet P.-Y., et al. New insights in the pathogenesis of high-altitude pulmonary edema. Prog Cardiovasc Dis 2010, 52:485-492.
29. Honigman B., Theis M.K., Koziol-McLain J., et al. Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med 1993, 118:587-592.
30. Schneider M., Bernasch D., Weymann J., et al. Susceptibility, rate of ascent and pre-acclimatization are major determinants for prevalence of acute mountain sickness (AMS). High Altitude Med Biol 2001, 2:1.
31. Hackett P., Roach R.C. High-altitude illness. N Engl J Med 2001, 345:107-114.
32. Roach R.C., Houston C.S., Honigman B., et al. How well do older persons tolerate moderate altitude?. West J Med 1995, 162:32-36.
33. Lyons T.P., Muza S.R., Rock P.B., et al. Prior acclimatization to 4300 m reduces acute mountain sickness symptomatology with reinduction. Hypoxia and Molecular Medicine 1993, Queen City Press, Burlington, VT. J.R. Sutton, G. Coates, C.S. Houston (Eds.).
34. Wu T.Y., Ding S.Q., Liu J.L., et al. Reduced incidence and severity of acute mountain sickness in Qinghai-Tibet railroad construction workers after repeated 7-month exposures despite 5-month low altitude periods. High Alt Med Biol 2009, 10:221-232.
35. Singh I., Khanna P.K., Srivastava M.C., et al. Acute mountain sickness. N Engl J Med 1969, 280:175-184.
36. Bert P. Barometric Pressure 1978, Undersea Medical Society, Bethesda, MD.
37. Barcroft J. Mountain sickness. Nature 1924, 2855:90-92.
38. Loeppky J.A., Icenogle M., Scotto P., et al. Ventilation during simulated altitude, normobaric hypoxia and normoxic hypobaria. Respir Physiol 1997, 107:231-239.
39. Loeppky J.A., Roach R.C., Maes D., et al. Role of hypobaria in fluid balance response to hypoxia. High Alt Med Biol 2005, 6:60-71.
40. Loeppky J.A., Scotto P., Roach R.C. Acute ventilatory response to simulated altitude, normobaric hypoxia, and hypobaria. Aviat Space Environ Med 1996, 67:1019-1022.
41. Roach R., Loeppky J. The role of hypobaria in high altitude illness. Hypoxia and the brain 1995, 277-283. Queen City Press, Burlington, VT. J. Sutton, C. Houston, G. Coates (Eds.).
42. Kallenberg K., Bailey D.M., Christ S., et al. Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. J Cereb Blood Flow Metab 2007, 27:1064-1071.
43. Schoonman G.G., Sándor P.S., Nirkko A.C., et al. Hypoxia-induced acute mountain sickness is associated with intracellular cerebral edema: a 3 T magnetic resonance imaging study. J Cereb Blood Flow Metab 2008, 28:198-206.
44. Ge R.L., Matsuzawa Y., Takeoka M., et al. Low pulmonary diffusing capacity in subjects with acute mountain sickness. Chest 1997, 111:58-64.
45. Grissom C.K., Roach R.C., Sarnquist F.H., et al. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 1992, 116:461-465.
46. Larson E.B., Roach R.C., Schoene R.B., et al. Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA 1982, 248:328-332.
47. Houston C.S., Dickinson J. Cerebral form of high-altitude illness. Lancet 1975, 2:758-761.
48. Matsuzawa Y., Kobayashi T., Fujimoto K., et al. Cerebral edema in acute mountain sickness. High altitude medicine 1992, 300-304. Shinshu Univ Press, Matsumoto, Japan. G. Ueda, J.T. Reeves, M. Sekiguchi (Eds.).
49. Wilson R. Acute high altitude illness in mountaineers and problems of rescue. Ann Intern Med 1973, 78:421-427.
50. Bartsch P., Swenson E.R., Paul A., et al. Hypoxic ventilatory response, ventilation, gas exchange, and fluid balance in acute mountain sickness. High Alt Med Biol 2002, 3:361-376.
51. Krasney J.A. A neurogenic basis for acute altitude illness. Med Sci Sports Exerc 1994, 26:195-208.
52. Fulco C.S., Rock P.B., Reeves J.T., et al. Effect of propranolol on acute mountain sickness (AMS) and well-being at 4,300 meters of altitude. Aviat Space Environ Med 1989, 60:679-683.
53. Valli G., Bonardi D., Campigotto F., et al. Relationship between individual ventilatory response and acute renal water excretion at high altitude. Respir Physiol Neurobiol 2008, 162:103-108.
54. Hansen J.E., Evans W.O. A hypothesis regarding the pathophysiology of acute mountain sickness. Arch Environ Health 1970, 21:666-669.
55. Ross R.T. The random nature of cerebral mountain sickness. Lancet 1985, 1:990-991.
56. Hackett P.H. The cerebral etiology of high-altitude cerebral edema and acute mountain sickness. Wilderness Environ Med 1999, 10:97-109.
57. Roach R.C., Hackett P.H. Frontiers of hypoxia research: acute mountain sickness. J Exp Biol 2001, 204:3161-3170.
58. Wilson M.H., Milledge J. Direct measurement of intracranial pressure at high altitude and correlation of ventricular size with acute mountain sickness: Brian Cummins' results from the 1985 Kishtwar expedition. Neurosurgery 2008, 63:970-974. [discussion 4-5].
59. Baumgartner R.W., Bartsch P., Maggiorini M., et al. Enhanced cerebral blood flow in acute mountain sickness. Aviat Space Environ Med 1994, 65:726-729.
60. Baumgartner R.W., Spyridopoulos I., Bartsch P., et al. Acute mountain sickness is not related to cerebral blood flow: a decompression chamber study. J Appl Physiol 1999, 86:1578-1582.
61. Otis S.M., Rossman M.E., Schneider P.A., et al. Relationship of cerebral blood flow regulation to acute mountain sickness. J Ultrasound Med 1989, 8:143-148.
62. Hackett P.H., Rennie I.D. Acute mountain sickness. Semin Respir Med 1983, 5:132-140.
63. Serrano-Duenas M. High-altitude headache. Expert Rev Neurother 2007, 7:245-248.
64. Broome J.R., Stoneham M.D., Beeley J.M., et al. High altitude headache: treatment with ibuprofen. Aviat Space Environ Med 1994, 65:19-20.
65. Burtscher M., Likar R., Nachbauer W., et al. Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ 1998, 316:1057-1058.
66. Burtscher M., Likar R., Nachbauer W., et al. Effects of aspirin during exercise on the incidence of high-altitude headache: a randomized, double-blind, placebo-controlled trial. Headache 2001, 41:542-545.
67. Sanchez del Rio M., Moskowitz M.A. High altitude headache. Lessons from headaches at sea level. Adv Exp Med Biol 1999, 474:145-153.
68. Ashina M., Bendtsen L., Jensen R., et al. Plasma levels of substance P, neuropeptide Y and vasoactive intestinal polypeptide in patients with chronic tension-type headache. Pain 1999, 83:541-547.
69. Brooks M.M. Methylene blue, an antidote to altitude sickness. J Aviat Med 1948, 18:298-299.
70. Krasney J.A. Cerebral hemodynamics and high altitude cerebral edema. Hypoxia: women at altitude 1997, 254-267. Queen City Publishers, Burlington. C.S. Houston, G. Coates (Eds.).
71. Krasney J.A., Curran-Everett D.C., Iwamoto J. High altitude cerebral edema: An animal model. Hypoxia: the adaptations 1990, 200-205. BC Dekker, Philadelphia, PA. J.R. Sutton, G. Coates, J.E. Remmers (Eds.).
72. Krasney J.A., Jensen J.B., Lassen N.A. Cerebral blood flow does not adapt to sustained hypoxia. J Cereb Blood Flow Metab 1990, 10:759-764.
73. Krasney J.A., Koehler R.C. Neural control of the circulation during hypoxia. Neural control of circulation 1980, 123-147. Academic Press, New York. M.J. Hughes, C.D. Barnes (Eds.).
74. Goadsby P.J. Pathophysiology of migraine. Neurol Clin 2009, 27:335-360.
75. Natah S.S., Srinivasan S., Pittman Q., et al. Effects of acute hypoxia and hyperthermia on the permeability of the blood-brain barrier in adult rats. J Appl Physiol 2009, 107:1348-1356.
76. Levels of evidence and grades of recommendation, Oxford Centre For Evidence-Based Medicine. 2003. (Accessed at .). http://www.cebm.net/levelspofpevidence.asp.
77. Pollard A.J. Altitude induced illness. BMJ 1992, 304:1324-1325.
78. Roach R.C., Icenogle M., Hinghofer-Szalkay H., et al. Exercise exacerbates acute mountain sickness at simulated high altitude. J Appl Physiol 2000, 88:581-585.
79. Nerin M.A., Palop J., Montano J.A., et al. Acute mountain sickness: influence of fluid intake. Wilderness Environ Med 2006, 17:215-220.
80. Richardson A., Watt P., Maxwell N. Hydration and the physiological responses to acute normobaric hypoxia. Wilderness Environ Med 2009, 20:212-220.
81. Hinckson E.A., Hamlin M.J., Wood M.R., et al. Game performance and intermittent hypoxic training. Br J Sports Med 2007, 41:537-539.
82. 2max. High Alt Med Biol 2007, 8:225-235.
83. Wilber R.L. Live high + train low: thinking in terms of an optimal hypoxic dose. Int J Sports Physiol Perform 2007, 2:223-238.
84. Wilber R.L., Stray-Gundersen J., Levine B.D. Effect of hypoxic "dose" on physiological responses and sea-level performance. Med Sci Sports Exerc 2007, 39:1590-1599.
85. Crowley J.S., Wesensten N., Kamimori G., et al. Effect of high terrestrial altitude and supplemental oxygen on human performance and mood. Aviat Space Environ Med 1992, 63:696-701.
86. Launay J.C., Nespoulos O., Guinet-Lebreton A., et al. Prevention of acute mountain sickness by low positive end-expiratory pressure in field conditions. Scand J Work Environ Health 2004, 30:322-326.
87. Savourey G., Caterini R., Launay J.C., et al. Positive end expiratory pressure as a method for preventing acute mountain sickness. Eur J Appl Physiol 1998, 77:32-36.
88. Consolazio C.F., Matoush L.O., Johnson H.L., et al. Effects of a high-carbohydrate diet on performance and clinical symptomology after rapid ascent to high altitude. Fed Proc 1969, 28:937-943.
89. Ried L.D., Carter K.A., Ellsworth A. Acetazolamide or dexamethasone for prevention of acute mountain sickness: a meta-analysis. J Wilderness Med 1994, 5:34-48.
90. Dumont L., Mardirosoff C., Tramer M. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ 2000, 321:267-272.
91. Basnyat B., Gertsch J.H., Holck P.S., et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol 2006, 7:17-27.
92. van Patot M.C., Leadbetter G., Keyes L.E., et al. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol 2008, 9:289-293.
93. Carlsten C., Swenson E.R., Ruoss S. A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Alt Med Biol 2004, 5:33-39.
94. Wright A.D., Bradwell A.R., Fletcher R.F. Methazolamide and acetazolamide in acute mountain sickness. Aviat Space Environ Med 1983, 54:619-621.
95. Hackett P.H., Roach R.C., Wood R.A., et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med 1988, 59:950-954.
96. Johnson T.S., Rock P.B., Fulco C.S., et al. Prevention of acute mountain sickness by dexamethasone. N Engl J Med 1984, 310:683-686.
97. Wright A.D., Beazley M.F., Bradwell A.R., et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness Environ Med 2004, 15:25-31.
98. Fischer R., Lang S.M., Leitl M., et al. Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur Respir J 2004, 23:47-52.
99. Kupper T.E., Strohl K.P., Hoefer M., et al. Low-dose theophylline reduces symptoms of acute mountain sickness. J Travel Med 2008, 15:307-314.
100. Gertsch J.H., Seto T.B., Mor J., et al. Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol 2002, 3:29-37.
101. Leadbetter G., Keyes L.E., Maakestad K.M., et al. Ginkgo biloba does-and does not-prevent acute mountain sickness. Wilderness Environ Med 2009, 20:66-71.
102. Moraga F.A., Flores A., Serra J., et al. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness Environ Med 2007, 18:251-257.
103. Roncin J.P., Schwartz F., D'Arbigny P. EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviat Space Environ Med 1996, 67:445-452.
104. van Patot M.C., Keyes L.E., Leadbetter G., et al. Ginkgo biloba for prevention of acute mountain sickness: does it work?. High Alt Med Biol 2009, 10:33-43.
105. Chow T., Browne V., Heileson H.L., et al. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med 2005, 165:296-301.
106. Gertsch J.H., Basnyat B., Johnson E.W., et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ 2004, 328:797.
107. Jafarian S., Gorouhi F., Salimi S., et al. Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Ann Neurol 2007, 62:273-277.
108. Bärtsch P., Merki B., Hofstetter D., et al. Treatment of acute mountain sickness by simulated descent: a randomised controlled trial. BMJ 1993, 306:1098-1101.
109. Pesce C., Leal C., Pinto H., et al. Determinants of acute mountain sickness and success on Mount Aconcagua (6962 m). High Alt Med Biol 2005, 6:158-166.
110. Ri-Li G., Chase P.J., Witkowski S., et al. Obesity: associations with acute mountain sickness. Ann Intern Med 2003, 139:253-257.
111. Burgess K.R., Johnson P., Edwards N., et al. Acute mountain sickness is associated with sleep desaturation at high altitude. Respirology 2004, 9:485-492.
112. Imray C.H., Myers S.D., Pattinson K.T., et al. Effect of exercise on cerebral perfusion in humans at high altitude. J Appl Physiol 2005, 99:699-706.
113. Bloch K.E., Turk A.J., Maggiorini M., et al. Effect of ascent protocol on acute mountain sickness and success at Muztagh Ata, 7546 m. High Alt Med Biol 2009, 10:25-32.
114. Forster P.J. Effect of different ascent profiles on performance at 4200m elevation. Aviat Space Environ Med 1985, 56:758-764.
115. Beidleman B.A., Muza S.R., Fulco C.S., et al. Intermittent altitude exposures reduce acute mountain sickness at 4300 m. Clin Sci (Lond) 2004, 106:321-328.
116. Lyons T.P., Muza S.R., Rock P.B., et al. The effect of altitude pre-acclimatization on acute mountain sickness during reexposure. Aviat Space Environ Med 1995, 66:957-962.
117. Beidleman B.A., Muza S.R., Fulco C.S., et al. Intermittent altitude exposures improve muscular performance at 4,300 m. J Appl Physiol 2003, 95:1824-1832.
118. Fulco C.S., Muza S.R., Beidleman B., et al. Exercise performance of sea-level residents at 4300 m after 6 days at 2200 m. Aviat Space Environ Med 2009, 80:955-961.
119. Beidleman B.A., Muza S.R., Fulco C.S., et al. Seven intermittent exposures to altitude improves exercise performance at 4300 m. Med Sci Sports Exerc 2008, 40:141-148.
120. Roach R.C., Greene E.R., Schoene R.B., et al. Arterial oxygen saturation for prediction of acute mountain sickness. Aviat Space Environ Med 1998, 69:1182-1185.
121. Baumgartner R.W., Bartsch P. Ataxia in acute mountain sickness does not improve with short-term oxygen inhalation. High Alt Med Biol 2002, 3:283-287.
122. Harvey T.C., Raichle M.E., Winterborn M.H., et al. Effect of carbon dioxide in acute mountain sickness: A rediscovery. Lancet 1988, II:639-641.
123. Bartsch P., Baumgartner R.W., Waber U., et al. Comparison of carbon-dioxide-enriched, oxygen-enriched, and normal air in treatment of acute mountain sickness. Lancet 1990, 336:772-775.
124. Kasic J.F., Smith H.M., Gamow R.I. A self-contained life support system designed for use with a portable hyperbaric chamber. Biomed Sci Instrum 1989, 25:79-81.
125. Kasic J.F., Yaron M., Nicholas R.A., et al. Treatment of acute mountain sickness: hyperbaric versus oxygen therapy. Ann Emerg Med 1991, 20:1109-1112.
126. Swenson E.R., MacDonald A., Vatheuer M., et al. Acute mountain sickness is not altered by a high carbohydrate diet nor associated with elevated circulating cytokines. Aviat Space Environ Med 1997, 68:499-503.
127. Golja P., Flander P., Klemenc M., et al. Carbohydrate ingestion improves oxygen delivery in acute hypoxia. High Alt Med Biol 2008, 9:53-62.
128. Lawless N.P., Dillard T.A., Torrington K.G., et al. Improvement in hypoxemia at 4600 meters of simulated altitude with carbohydrate ingestion. Aviat Space Environ Med 1999, 70:874-878.
129. West J.B. The Qinghai-Tibet railway. High Alt Med Biol 2008, 9:1-2.
130. Gerard A.B., McElroy M.K., Taylor M.J., et al. Six percent oxygen enrichment of room air at simulated 5,000 m altitude improves neuropsychological function. High Alt Med Biol 2000, 1:51-61.
131. 2 enrichment. High Alt Med Biol 2003, 4:389-398.
132. Esbaugh A.J., Tufts B.L. The structure and function of carbonic anhydrase isozymes in the respiratory system of vertebrates. Respir Physiol Neurobiol 2006, 154:185-198.
133. Maren T.H., Sanyal G. The activity of sulfonamides and anions against the carbonic anhydrases of animals, plants, and bacteria. Annu Rev Pharmacol Toxicol 1983, 23:439-459.
134. Hackett P.H., Roach R.C. Medical therapy of altitude illness. Ann Emerg Med 1987, 16:980-986.
135. Swenson E.R. Carbonic anhydrase inhibitors and ventilation: a complex interplay of stimulation and suppression [editorial; comment]. Eur Respir J 1998, 12:1242-1247.
136. Swenson E.R. Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol 2006, 151:209-216.
137. Swenson E.R., Teppema L.J. Prevention of acute mountain sickness by acetazolamide: as yet an unfinished story. J Appl Physiol 2007, 102:1305-1307.
138. Droma Y., Hanaoka M., Basnyat B., et al. Symptoms of acute mountain sickness in Sherpas exposed to extremely high altitude. High Alt Med Biol 2006, 7:312-314.
139. Hillenbrand P., Pahari A.K., Soon Y., et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial. Wilderness Environ Med 2006, 17:87-93.
140. Kayser B., Hulsebosch R., Bosch F. Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Alt Med Biol 2008, 9:15-23.
141. Hackett P.H., Schoene R.B., Winslow R.M., et al. Acetazolamide and exercise in sojourners to 6,300 meters-a preliminary study. Med Sci Sports Exerc 1985, 17:593-597.
142. Garske L.A., Brown M.G., Morrison S.C. Acetazolamide reduces exercise capacity and increases leg fatigue under hypoxic conditions. J Appl Physiol 2003, 94:991-996.
143. Bradwell A.R., Dykes P.W., Coote J.H., et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet 1986, I:1001-1005.
144. Jonk A.M., van den Berg I.P., Olfert I.M., et al. Effect of acetazolamide on pulmonary and muscle gas exchange during normoxic and hypoxic exercise. J Physiol 2007, 579:909-921.
145. Stager J.M., Tucker A., Cordain L., et al. Normoxic and acute hypoxic exercise tolerance in man following acetazolamide. Med Sci Sport Exerc 1990, 22:178-184.
146. Wright A.D., Winterborn M.H., Forster P.J., et al. Carbonic anhydrase inhibition in the immediate therapy of acute mountain sickness. J Wilderness Med 1994, 5:49-55.
147. Maren T.H. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 1967, 47:595-781.
148. Lichter P.R. Reducing side effects of carbonic anhydrase inhibitors. Ophthalmology 1981, 88:266-269.
149. Levine B.D., Yoshimura K., Kobayashi T., et al. Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 1989, 321:1707-1713.
150. Rock P.B., Johnson T.S., Larsen R.F., et al. Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest 1989, 95:568-573.
151. Basu M., Sawhney R.C., Kumar S., et al. Glucocorticoids as prophylaxis against acute mountain sickness. Clin Endocrinol (Oxf) 2002, 57:761-767.
152. Bernhard W.N., Schalick L.M., Delaney P.A., et al. Acetazolamide plus low-dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviat Space Environ Med 1998, 69:883-886.
153. Keller H.R., Maggiorini M., Bärtsch P., et al. Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial. BMJ 1995, 310:1232-1235.
154. Ferrazzini G., Maggiorini M., Kriemler S., et al. Successful treatment of acute mountain sickness with dexamethasone. Br Med J (Clin Res Ed) 1987, 294:1380-1382.
155. Chan C.W., Hoar H., Pattinson K., et al. Effect of sildenafil and acclimatization on cerebral oxygenation at altitude. Clin Sci (Lond) 2005, 109:319-324.
156. Maggiorini M., Brunner-La Rocca H.P., Peth S., et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006, 145:497-506.
157. Fischer R., Lang S.M., Steiner U., et al. Theophylline improves acute mountain sickness. Eur Respir J 2000, 15:123-127.
158. Chen C.H., Chen A.C., Liu H.J. Involvement of nitric oxide and N-methyl-D-aspartate in acute hypoxic altitude convulsion in mice. Aviat Space Environ Med 1997, 68:296-299.
159. Xie J., Lu G., Hou Y. Role of excitatory amino acids in hypoxic preconditioning. Biol Signals Recept 1999, 8:267-274.
160. Lysakowski C., Von Elm E., Dumont L., et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clin Sci (Lond) 2004, 106:279-285.
161. Dumont L., Lysakowski C., Tramer M.R., et al. Magnesium for the prevention and treatment of acute mountain sickness. Clin Sci (Lond) 2004, 106:269-277.
162. Dubey A.K., Shankar P.R., Upadhyaya D., et al. Ginkgo biloba-an appraisal. Kathmandu Univ Med J (KUMJ) 2004, 2:225-229.
163. Bailey D.M., Davies B. Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude. High Alt Med Biol 2001, 2:21-29.
164. Baillie J.K., Thompson A.A., Irving J.B., et al. Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM 2009, 102:341-348.
165. Teppema L.J., Bijl H., Romberg R.R., et al. Antioxidants reverse depression of the hypoxic ventilatory response by acetazolamide in man. J Physiol 2006, 572:849-856.
166. Aoki V.S., Robinson S.M. Body hydration and the incidence and severity of acute mountain sickness. J Appl Physiol 1971, 31:363-367.
167. Gray G.W., Bryan A.C., Frayser R., et al. Control of acute mountain sickness. Aerospace Med 1971, 42:81-84.
168. Jain S.C., Singh M.V., Sharma V.M., et al. Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. Int J Biometeorol 1986, 30:293-300.
169. Larsen R.F., Rock P.B., Fulco C.S., et al. Effect of spironolactone on acute mountain sickness. Aviat Space Environ Med 1986, 57:543-547.
170. Sutton J.R., Houston C.S., Mansell A.L., et al. Effect of acetazolamide on hypoxemia during sleep at high altitude. N Engl J Med 1979, 301:1329-1331.
171. Beaumont M., Goldenberg F., Lejeune D., et al. Effect of zolpidem on sleep and ventilatory patterns at simulated altitude of 4,000 meters. Am J Respir Crit Care Med 1996, 153:1864-1869.
172. Dubowitz G. Effect of temazepam on oxygen saturation and sleep quality at high altitude: randomised placebo controlled crossover trial. BMJ 1998, 316:587-589.
173. Nicholson A.N., Smith P.A., Stone B.M., et al. Altitude insomnia: studies during an expedition to the Himalayas. Sleep 1988, 11:354-361.
174. Nickol A.H., Leverment J., Richards P., et al. Temazepam at high altitude reduces periodic breathing without impairing next-day performance: a randomized cross-over double-blind study. J Sleep Res 2006, 15:445-454.
175. Jafarian S., Gorouhi F., Salimi S., et al. Low-dose gabapentin in treatment of high-altitude headache. Cephalalgia 2007, 27:1274-1277.
176. Luks A.M., Henderson W.R., Swenson E.R. Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Alt Med Biol 2007, 8:131-138.
177. Luks A.M. Which medications are safe and effective for improving sleep at high altitude?. High Alt Med Biol 2008, 9:195-198.
178. Fradette C., Batonga J., Teng S., et al. Animal models of acute moderate hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulation of CYP3A6 and P-glycoprotein in liver. Drug Metab Dispos 2007, 35:765-771.
179. Jurgens G., Christensen H.R., Brosen K., et al. Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. Clin Pharmacol Ther 2002, 71:214-220.
180. Streit M., Goggelmann C., Dehnert C., et al. Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). Eur J Clin Pharmacol 2005, 61:39-46.
181. Maloney J., Wang D., Duncan T., et al. Plasma vascular endothelial growth factor in acute mountain sickness. Chest 2000, 118:47-52.
182. Dorward D.A., Thompson A.A., Baillie J.K., et al. Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness. Respir Med 2007, 101:587-594.
183. Walter R., Maggiorini M., Scherrer U., et al. Effects of high-altitude exposure on vascular endothelial growth factor levels in man. Eur J Appl Physiol 2001, 85:113-117.
184. Severinghaus J.W. Hypothetical roles of angiogenesis, osmotic swelling, and ischemia in high-altitude cerebral edema. J Appl Physiol 1995, 79:375-379.
185. Tissot van Patot M.C., Leadbetter G., Keyes L.E., et al. Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol 2005, 98:1626-1629.